Viatris Inc. (VTRS) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $15.04: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Elevated put/call ratio: 1.44; Below-average business quality.
Viatris is a global healthcare company supplying generics, brands, and innovative medicines to approximately 1 billion patients in 165+ countries, with 2025 total revenues of 14.30 billion dollars. Revenue comes from generic drug sales, established branded products, and an... Read more
Sell if holding. Engine safety override at $15.04: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Elevated put/call ratio: 1.44; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.5/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMSupplierlimited manufacturing and third-party API suppliers10-K Item 1A: 'We have a limited number of manufacturing facilities and certain third-party suppliers produce a substantial portion of our API and products'
- MEDIUMGeographicChina VBP pricing10-K Item 1A: 'In China, pricing pressures have increased in recent years ... with some bidders reducing the price of their products by as much as 96%'
Material Events(8-K, last 90d)
- 2026-02-26Item 2.05MEDIUMOn February 26, 2026, Viatris committed to restructuring including a global workforce reduction of up to approximately 10%. Activities to be completed primarily over three years following enterprise-wide strategic review.SEC filing →
- 2026-02-03Item 5.02MEDIUMBrian Roman, Chief Legal Officer, transitioned from role effective February 9, 2026, remaining as employee until April 1, 2026. Successor: Matthew Maletta named CLO February 9, 2026, formerly EVP/CLO at Endo, Inc. 2015-2025.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Unprofitable operations — net margin -24.6%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.04: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Elevated put/call ratio: 1.44; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $14.25. Score 5.5/10, moderate confidence.
Take-profit target: $14.91 (-1.0% upside). Prior stop was $14.25. Stop-loss: $14.25.
Target reached (-9.1% upside); Quality below floor (3.1 < 4.0).
Viatris Inc. trades at a P/E of N/A (forward 5.6). TrendMatrix value score: 8.1/10. Verdict: Sell.
18 analysts cover VTRS with a consensus score of 3.8/5. Average price target: $16.
What does Viatris Inc. do?Viatris is a global healthcare company supplying generics, brands, and innovative medicines to approximately 1 billion...
Viatris is a global healthcare company supplying generics, brands, and innovative medicines to approximately 1 billion patients in 165+ countries, with 2025 total revenues of 14.30 billion dollars. Revenue comes from generic drug sales, established branded products, and an expanding innovative pipeline. The company has 27 manufacturing sites and 1,400+ approved molecules.